Shares of Trevi Therapeutics jumped 13.10%, or $2.27, to $19.64 in Friday morning trading, as investor attention turned to the clinical-stage biopharmaceutical company's presence at a major European medical conference focused on chronic cough treatment.

The New Haven, Connecticut-based company has had representatives at the European Respiratory Society's Cough Conference in London this week, running from Wednesday through Friday. Trevi Chief Executive Jennifer Good and Chief Development Officer James Cassella have been presenting the company's clinical trial results for Haduvio, its lead investigational therapy, at the conference, discussing findings the company says demonstrate the drug's advantages in treating chronic cough associated with several difficult-to-manage lung conditions.

Haduvio, an oral extended-release formulation of nalbuphine, is being developed by Trevi to treat chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, as well as chronic cough associated with non-IPF interstitial lung disease and refractory chronic cough, a condition that persists without an identifiable underlying cause. According to the company, Haduvio is the first and only investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials spanning both IPF-related chronic cough and refractory chronic cough populations. The drug works by acting on the cough reflex pathway both centrally and peripherally, functioning as what the company describes as a kappa agonist and mu antagonist, targeting opioid receptors involved in regulating the chronic cough response.

Trevi's presentation in........

© International Business Times